Mesoblast cash forecast

Hi all

Not sure if anybody has put this up yet, but thought I'd share my high level notes on MSB's cash forecast without taking into account any revenue from Temcell:

Opening Balance December 2016 = US$33.9m
MNK January 2017 = +US$21.7m
Placement March 2017 = +US$40.0m
Q3 cash outflow = -US$27.0m

Forecast March17 = US$68.6m

Aust Gov rebate = +US$5.0m
Q4 cash outflow = -US$27.0m

Forecast June17 = US$46.6m
FY18 Q1 outflow = -US$27.0m
**MNK deal = +US$XXXm?

Forecast Sep17=US$19.6m +US$XXXm?

Other than the MNK deal, here are the potential sources of material cash injections throughout 2017/early 2018:
- Temcell sales ramping up
- Japan/China deal on RA/CLBP/CHF (can be approved on P2 data)
- RA partner (US)
- CHF partner (US)
- Priority review voucher (aGVHD); potentially worth tens or US$100+ million.